BioXcel Therapeutics Inc at JPMorgan Healthcare Conference Transcript
All right. Good morning, everybody. Nice to see all of you. Thank you so much for being here today. My name is Chris Aholt. I'm an associate in the health care group at JPMorgan. Today, I have the pleasure of introducing Vimal Mehta, Cofounder and CEO of BioXcel Therapeutics. Vimal is planning on doing about a 20-minute presentation followed by Q&A, and I'll have a few members of his management team up here to help out with Q&A. Thank you very much.
Thank you, Chris. Good morning, everyone. I'm very pleased to be here to provide the update on BioXcel Therapeutics and the exciting year we have ahead. First of all, I'd like to thank everyone who is attending as well as JPMorgan for inviting us for this opportunity. BioXcel Therapeutics is an AI-driven company that's developing transformative medicines in neuroscience and immuno-oncology. Those are the 2 key focus areas, and our underlying platform is our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |